Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

Slides:



Advertisements
Similar presentations
IRESSA A Case Study in Personalised Medicine Dr Rose McCormack
Advertisements

Inhibition of the mTOR and MAPK pathways in the treatment of osteosarcoma Kathleen M. Diehl, M.D. FACS Assistant Professor University of Michigan.
1 Caroline Laboulle Alexandra Mascret Valerio Pilato.
21th WCC, Shenzhen, China, Aug 19, 2010 Guo-Liang Jiang, MD, FACR Min Fan, MD, Jiayan Chen, MD Fudan University Shanghai Cancer Center Combination of radiation.
New Perspectives in Cancer Therapy Óren Smaletz Programa de Oncologia Hospital Israelita Albert Einstein.
A Mediating Effect of AKT in EGFR Signal to Osteosarcomas in a Clinical Study Huiyun Wu, Adriana Gonzalez, and Yu Shyr Vanderbilt-Ingram Cancer Center,
CI-1 IRESSA ® (ZD1839) Monotherapy for Non-Small Cell Lung Cancer (NSCLC) Oncologic Drugs Advisory Committee Meeting September 24, 2002 Oncologic Drugs.
Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma Sarkheil Mehdi Hematologist-Oncologist.
 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Breast Cancer slide presentation is not an independent educational.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Drug Development.
Anticancer Therapy: Kinase Inhibitors Charles Harrell.
Jennie Bell CMGS/ACC Spring meeting 14 th April 2010.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Monoclonal antibodies in solid tumors.
In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.
CS-1 Results of the Phase 3 Clinical Trials of Abraxane vs. Taxol in Metastatic Breast Cancer William J. Gradishar, MD, FACP Professor of Medicine Northwestern.
Molecular Cancer Targets Wester H Clin Cancer Res 2007;13:
New Developments in Cancer Treatment Dulcinea Quintana, MD.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,
Hormonal Agents Estrogen & Androgen Inhibitors Gonadotropin-Releasing Hormone Agonists Aromatase Inhibitors Tamoxifen Leuprolide Aminogluthethimide.
Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”
Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.
Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.
ONCOLOGY Drug Development Fadi Sami Farhat, MD ONCOLOGY Drug Development Fadi Sami Farhat, MD Hematology Oncology
Underlying Principles and Future Targets for Molecular Therapy of SCCHN Prof. Tim H. Brümmendorf Dept. of Hematology and Oncology University Hospital Eppendorf.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Developing medicines for the future and why it is challenging Angela Milne.
Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)
 Angiogenesis Signaling Cascades EGFR PI3K MAPK Nucleus Gene Activation Cell Cycle Progression M G1G1 S G2G2 Fos P P MAPK = mitogen-activated protein.
Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology
© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
North Central Cancer Treatment Group Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine (PGE) versus Erlotinib-Gemcitabine (GE) in Patients.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
PHL 616 Drug Discovery & Development Fifth Lecture By Abdelkader Ashour, Ph.D. Phone:
Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.
Prof. Jae Heon, Jeong/R2 Cheol Hyun, Lee J of Clinical oncology, Vol 31 Number 4, Feb.1, 2013.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
EGFR exon 20 insertion mutations
Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.
Wolfram C. M. Dempke SaWo Oncology Ltd May 13, 2017
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Necitumumab Drugbank ID :DB09559 Molecular Weight (Daltons) :144800
Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 
Targeting signal transduction
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Intervista a Lucio Crinò
Sustaining Proliferative Signaling and Evading Growth Suppressors
Underlying Mechanisms for Distant Metastasis - Molecular Biology
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Figure 4 Possible combination therapies CDK4/6 inhibitors
Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma  Darshil J. Shah, MD, MPH, Roxana S. Dronca,
Figure 1 A schematic representation of the HER2 signalling pathway
Volume 131, Issue 5, Pages (November 2006)
Nintedanib: preclinical data
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
Volume 131, Issue 5, Pages (November 2006)
RESEARCH IN MOLECULAR THERAPI
Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer  Edward.
Clinical courses of patients.
Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer  Thomas Winder, Heinz–Josef.
SRC and STAT Pathways Journal of Thoracic Oncology
Volume 8, Issue 4, Pages (October 2005)
Tyrosine kinase inhibitors
Forest plot of (left) overall survival and (right) progression-free survival for gefitinib versus docetaxel in the INTEREST (IRESSA NSCLC Trial Evaluating.
Presentation transcript:

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years

1990 – compound identified in a screen for PKC inhibitors 1992 – First batch of Gleevec synthesized 1996 – In vivo activity shown in BCR-ABL transformed cells in mice June 1998 – first patient with CML treated June 2000 – Phase III trials initiated Nov 2001 – Approved in Europe and Japan for CML May 2001 – Approved by FDA for CML June 1999 – Phase II trials initiated Feb 2001 – NDA submitted to FDA for CML Feb 2002 – Approved by FDA for GIST Clinical developmentDiscovery Gleevec development timeline

Epidermal growth factor receptor (EGFR)

Expressed in a variety of solid tumours –Correlates with disease progression, poor survival and response to therapy Upon ligand binding, receptor dimerisation activates tyrosine kinase activity and tyrosine autophosphorylation. Leads to –cell proliferation –increased angiogenesis –invasion and metastasis –decreased apoptosis

Example: Gifitinib (Iressa) In preclinical studies of cell lines and human tumor xenografts, gefitinib produced growth inhibition in lung, prostate, breast, colon, and ovarian cancers Gefitinib enhance the antitumor activity of cytotoxic agents, radiation therapy, and hormone therapies Surprisingly, however, the effectiveness of gefitinib as an antitumor agent did not seem to correlate with EGFR expression either in vitro or in vivo

ANTI-EGFR (IRESSA) IN SECOND-LINE METASTATIC LUNG CANCER Myc Cyclin D1 JunFos PP DNA K K Ligand EGFR K K pY MAPK MEK-1 PI3-K RasRaf SOS Grb-2 PTEN Akt STAT Proliferation/ maturation Survival/ apoptosis  Angiogenesis Metastasis K pY Tyrosine kinase Phosphorylated tyrosine residue IRESSA     

Phase I Studies for Iressa Phase I studies showed antitumor responses in advanced cancers of the lung, head and neck, prostate, ovary, and colon EGFR status of the tumor was not used as a criterion for enrollment of patients into the Phase I studies –At all dose levels, significant decreases in MAPK and Ki-67, significant increases in the cyclin-dependent kinase inhibitor p27KIP1 and in rates of apoptosis –One study found a significant decrease in phosphorylated EGFR pre- and post-treatment

Phase II/III trials Multicenter Phase II trials: –IRESSA Dose Evaluation in Advanced Lung Cancer (IDEAL)-1 global trial with 210 patients –IDEAL-2 US trial with 221 patients Phase III trial first-line therapy for NSCLC, given continuously: –IRESSA NSCLC Trials Assessing Combination Therapy (INTACT)-1 with cisplatin/gemcitabine –INTACT-2 with carboplatin/paclitaxel

Phase II: IDEAL trials

INTACT-1 Patient Characteristics

Tumor Responses

INTACT-1 Progression-free Survival

INTACT-1 Overall Survival

INTACT-2 Design